A new network meta-analysis published in JACC: Advances provides important evidence — and a reminder to interpret comparative effectiveness carefully. Laino and colleagues evaluated 35 randomized trials involving 8,648 patients. The network meta-analysis included 30 trials and 8,187 patients.
Read More
The American College of Cardiology has released its 2026 Expert Consensus Decision Pathway on Resistant Hypertension, published in JACC. This document provides a practical framework to translate evidence into clinical…
Read More
A timely State-of-the-Art Review by Khan and colleagues in CJASN provides a comprehensive look at how the management of resistant hypertension is evolving. The first step remains fundamental: Is this truly resistant…
Read More
A timely Review in Nature Reviews Nephrology places the aldosterone–mineralocorticoid receptor (MR) axis at the center of the cardiovascular–kidney–metabolic (CKM) continuum. The concept is compelling: inappropriate MR…
Read More
A new drug-level network meta-analysis including 10 RCTs and 2,865 patients provides an interesting perspective on therapies targeting the aldosterone-related sodium-retention pathway. Compared with placebo, office…
Read More
For years, pharmacologic targeting of aldosterone has largely meant blocking its action at the mineralocorticoid receptor. Now, aldosterone synthesis itself has become a therapeutic target. In a timely article published…
Read More
In obstructive sleep apnoea, that question may be more important than we think. A timely review by Gruber et al. in the European Respiratory Review highlights a frequently overlooked phenotype: nocturnal hypertension…
Read MoreNo insights match your search.